Loading...

CGON CG ONCOLOGY INC Product Launches 8-K Filing

CG N

CGN

CG ONCOLOGY INC

(CGON)

2024 8-K

Show Summary

Summary

Corporate Presentation Update

Clinical Trial Update

Financial Statements

Appointed Directors

Financial Statements

Product Expansion

Financial Results

Clinical Trial Update

Executive Agreements

Clinical Trial Results

Financial Results

External Links:

CG Oncology reported positive results from its Phase 3 trial of cretostimogene for bladder cancer, showing a 74.5% complete response rate among patients, with no severe adverse events reported.

AI Assistant

CG ONCOLOGY INC

2024

8 K

Find Answers

Ask about any part of the document to get insights, explanations, or key details.